Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

17 May 2017 07:00

RNS Number : 3487F
Ideagen PLC
17 May 2017
 

This announcement contains inside information.

 

 

17 May 2017

 

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to provide an update on trading for the year ended 30 April 2017 ahead of the announcement of its full year results on or around 18 July 2017.

 

The Board is pleased to report that results to 30 April 2017 are expected to be in line with market expectations and that trading was once again robust across all key verticals, with particular success within the Life Sciences, Aviation and Financial sectors. The Group delivered organic revenue growth* of approximately 10 per cent together with further contributions from all four acquisitions made during the year. This represents the Group's eighth consecutive year of revenue and adjusted EBITDA** growth.

 

The Group expects to report revenue of approximately £27.1million, (FY2016: £21.9 million) and adjusted EBITDA** of approximately £7.8 million (FY2016: £6.3 million), both having increased by approximately 24%, and a significant increase in adjusted EPS***, which continues to be an important financial metric for the Group.

 

The Board is confident that the transition from a traditional 'perpetual licence' business model to a 'subscription licence' model is well underway, as evidenced by a significant increase in the run-rate of recurring revenues. This has been driven primarily by the success of Coruson, our SaaS based enterprise Risk and Safety Management solution which is allowing the Group to win larger contracts and grow high visibility, subscription-based revenue. 

 

Cash generation was extremely strong at the end of the financial year and accordingly net cash at 30 April 2017 was significantly ahead of market forecasts at £4.2 million (31 October 2016: £4.8 million), even after paying £4.6 million of consideration for the acquisitions of IPI Solutions and Gael (deferred) and £0.3 million in dividends. The Board expects to report that cash generated by operations will be in excess of 100% of adjusted EBITDA**.

 

 

David Hornsby, Chief Executive, commented: "We are pleased to report that the Group has continued to perform well in delivering another year of high quality earnings growth underpinned by strong cash generation. We have also made four important acquisitions which have provided scale, product capability and recurring revenues. We continue to grow organically and to increase the percentage of our revenues derived from recurring business. The Group has significant contracted work in progress and a strong pipeline of new business opportunities which provides the Board with confidence for the current year and beyond."

 

* FY2016 comparator prepared on a proforma basis as if these acquisitions had occurred during that year

**Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and other exceptional items.

***Adjusted diluted earnings per share

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Chief Executive

 

Graeme Spenceley, Finance Director

 

 

 

finnCap Limited

020 7220 0500

Stuart Andrews/Henrik Persson/James Thompson (Nomad)

 

Stephen Norcross (Corporate Broking)

 

 

 

 

 

 About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in GRC (Governance, Risk and Compliance) and Content and Clinical solutions with a primary focus on organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete information lifecycle solutions that enable organisations to reduce risk, meet their regulatory and compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 3,000 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDQLFFDEFXBBK
Date   Source Headline
24th Sep 201810:42 amRNSHolding(s) in Company
17th Sep 20184:42 pmRNSExercise of Options and Total Voting Rights
17th Sep 20184:33 pmRNSHolding(s) in Company
13th Sep 20185:00 pmRNSClosing of conditional Placing to raise £20m
13th Sep 201811:30 amRNSProposed Placing to raise £20 million
5th Sep 20187:00 amRNSAcquisition of InspectionXpert Inc
3rd Sep 20182:36 pmRNSExercise of Options and Total Voting Rights
15th Aug 201812:23 pmRNSHolding(s) in Company
13th Aug 20183:18 pmRNSHolding(s) in Company
13th Aug 20183:05 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Aug 20181:08 pmRNSHolding(s) in Company
23rd Jul 20183:27 pmRNSIssue of Equity
17th Jul 20187:00 amRNSUnaudited Preliminary Results
18th Jun 20183:38 pmRNSExercise of Options and Total Voting Rights
11th Jun 20185:00 pmRNSIssue of Equity and Total Voting Rights
22nd May 20183:59 pmRNSIssue of Shares under Share Incentive Plan and TVR
15th May 20183:10 pmRNSExercise of Options and Total Voting Rights
9th May 20187:00 amRNSExercise of Options and Total Voting Rights
8th May 20187:00 amRNSPre-Close Trading Update and Board Changes
18th Apr 201810:12 amRNSIssue of Equity
12th Apr 201810:35 amRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
6th Apr 20187:00 amRNSAcquisition of Medforce Technologies Inc
26th Mar 201812:38 pmRNSHolding(s) in Company
16th Mar 20187:00 amRNSIssue of Shares under Share Incentive Plan and TVR
6th Mar 20183:58 pmRNSExercise of Options and Total Voting Rights
14th Feb 20187:00 amRNSIssue of Equity
23rd Jan 20187:00 amRNSInterim Results
11th Jan 20187:00 amRNSIssue of Equity
13th Dec 201710:18 amRNSDirector Dealing
11th Dec 20172:26 pmRNSIssue of Equity
4th Dec 201712:37 pmRNSExercise of Options and Total Voting Rights
23rd Nov 20177:00 amRNSContract Win
10th Nov 20173:07 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Nov 20171:26 pmRNSExercise of Options and Total Voting Rights
7th Nov 20177:00 amRNSTrading Update
1st Nov 20175:18 pmRNSPDMR / PCA Dealing
30th Oct 20171:33 pmRNSResult of AGM
25th Oct 20177:00 amRNSExercise of Options and Total Voting Rights
23rd Oct 201710:55 amRNSExercise of Options and Total Voting Rights
16th Oct 20173:30 pmRNSExercise of Options and Total Voting Rights
9th Oct 20174:09 pmRNSIssue of shares under the Share Incentive Plan
6th Oct 20173:13 pmRNSNotice of AGM
27th Sep 20174:28 pmRNSExercise of Options and Total Voting Rights
20th Sep 201710:08 amRNSHolding(s) in Company
4th Sep 20177:00 amRNSBoard Appointment
1st Sep 20173:06 pmRNSIssue of shares under a Share Incentive Plan
11th Aug 20173:00 pmRNSHolding(s) in Company
11th Aug 20178:00 amRNSHolding(s) in Company
10th Aug 20171:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.